Press Releases 3SBio Inc.

Equities

1530

KYG8875G1029

Delayed Hong Kong S.E. Other stock markets 07:54:22 25/06/2024 BST			5-day change	1st Jan Change
5.95 ^HKD	-1.16%		-4.03%	-20.88%

05-29	3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection	MT
04-22	3Sbio Inc. Announces Management Changes	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced	25/08/23	PR
3SBio : 2023 Interim Results Presentation	24/08/23	PU
3SBio : 2022 ESG Report	28/04/23	PU
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%	22/03/23	PR
3SBio : 2022 Interim Results Presentation	24/08/22	PU
3SBio : 1530.HK) _ Prospectus	24/06/22	PU
3SBio : 2021 ESG Report	24/05/22	PU
3SBio : 2021Annual Report	29/04/22	PU
3SBio : announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses	30/03/22	PU
3SBIO : 2021Annual Results	28/03/22	PU
3SBio : Documents on Display	21/12/21	PU
3SBio : announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development	26/08/21	PU
3SBio : announces 2020 annual results, tapping integrated platform advantages for steady growth	30/03/21	PU
3SBio : PRELIMINARY RESULTS OF SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2020	26/02/21	PU
3SBio : Sunshine Guojian Selects Verseau’s VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration	14/12/20	PU
3SBio Inc. : received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212	23/11/20	PR
3SBio : Announces Acceptance of IND application for bevacizumab biosimilar in China	14/09/20	PU
3SBio : VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE IND APPLICATION FOR BEVACIZUMAB BIOSIMILAR IN MAINLAND CHINA	14/09/20	PU
3SBio : MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry	01/09/20	PU
3SBio : WITHDRAWAL OF LISTING OF THE ZERO COUPON CONVERTIBLE BONDS DUE 2022	28/08/20	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases 3SBio Inc.

Equities

1530

KYG8875G1029

Press Releases

Filters